Advertisement

Topics

Selvita and the Leukemia & Lymphoma Society announce partnership to advance SEL 120 into phase I for patients with AML

10:35 EDT 8 Aug 2017 | CentreWatch

Selvita S.A. and The Leukemia & Lymphoma Society have announced a partnership to co-fund further preclinical and clinical development of a targeted therapy to treat patients with acute myeloid leukemia (AML). Selvita has discovered and is developing SEL120, a therapy that targets the cyclin-dependent kinase 8 (CDK8) protein, which plays a unique and critical role […]

The post Selvita and the Leukemia & Lymphoma Society announce partnership to advance SEL 120 into phase I for patients with AML appeared first on CenterWatch News Online.

Original Article: Selvita and the Leukemia & Lymphoma Society announce partnership to advance SEL 120 into phase I for patients with AML

NEXT ARTICLE

More From BioPortfolio on "Selvita and the Leukemia & Lymphoma Society announce partnership to advance SEL 120 into phase I for patients with AML"

Quick Search
Advertisement
 

Relevant Topic

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...